ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
ENDRA Life Sciences (NASDAQ: NDRA) has been granted its 17th European patent (EP4247282) for a novel method of monitoring tissue temperature during minimally invasive thermal surgical procedures using their TAEUS® system. The patent relates to monitoring tissue ablation and enables integration with existing ablation systems. The technology is applicable to microwave and radiofrequency thermal ablation procedures, which are growing globally as less invasive alternatives to open surgery. This addition brings ENDRA's global intellectual property portfolio to 82 issued patents across key markets including the United States, Europe, and China.
ENDRA Life Sciences (NASDAQ: NDRA) ha ricevuto il suo 17° brevetto europeo (EP4247282) per un nuovo metodo di monitoraggio della temperatura dei tessuti durante procedure chirurgiche termiche minimamente invasive utilizzando il loro sistema TAEUS®. Il brevetto riguarda il monitoraggio dell'ablazione dei tessuti e consente l'integrazione con i sistemi di ablazione esistenti. La tecnologia è applicabile a procedure di ablazione termica a microonde e radiofrequenza, che stanno crescendo a livello globale come alternative meno invasive alla chirurgia aperta. Questo nuovo brevetto porta il portafoglio globale di proprietà intellettuale di ENDRA a 82 brevetti rilasciati in mercati chiave, tra cui Stati Uniti, Europa e Cina.
ENDRA Life Sciences (NASDAQ: NDRA) ha recibido su 17ª patente europea (EP4247282) para un nuevo método de monitoreo de la temperatura del tejido durante procedimientos quirúrgicos térmicos mínimamente invasivos utilizando su sistema TAEUS®. La patente se relaciona con el monitoreo de la ablación de tejidos y permite la integración con sistemas de ablación existentes. La tecnología es aplicable a procedimientos de ablación térmica por microondas y radiofrecuencia, que están creciendo globalmente como alternativas menos invasivas a la cirugía abierta. Esta adición lleva el portafolio global de propiedad intelectual de ENDRA a 82 patentes emitidas en mercados clave, incluidos Estados Unidos, Europa y China.
ENDRA Life Sciences (NASDAQ: NDRA)는 그들의 TAEUS® 시스템을 사용하여 최소 침습 열수술 절차 중 조직 온도를 모니터링하기 위한 새로운 방법에 대해 17번째 유럽 특허(EP4247282)를 받았습니다. 이 특허는 조직 절제 모니터링과 관련이 있으며 기존 절제 시스템과의 통합을 허용합니다. 이 기술은 마이크로웨이브 및 라디오 주파수 열 절제 절차에 적용 가능하며, 이는 개복 수술에 대한 덜 침습적인 대안으로 전 세계에서 성장하고 있습니다. 이 추가는 ENDRA의 전 세계 지식 재산 포트폴리오를 82개의 발급된 특허로 늘리며, 주요 시장으로는 미국, 유럽 및 중국이 포함됩니다.
ENDRA Life Sciences (NASDAQ: NDRA) a obtenu son 17ème brevet européen (EP4247282) pour une nouvelle méthode de surveillance de la température des tissus lors de procédures chirurgicales thermiques peu invasives utilisant leur système TAEUS®. Le brevet concerne la surveillance de l'ablation des tissus et permet l'intégration avec les systèmes d'ablation existants. La technologie est applicable aux procédures d'ablation thermique par micro-ondes et radiofréquence, qui croissent à l'échelle mondiale en tant qu'alternatives moins invasives à la chirurgie ouverte. Cet ajout porte le portefeuille mondial de propriété intellectuelle d'ENDRA à 82 brevets délivrés sur des marchés clés, y compris les États-Unis, l'Europe et la Chine.
ENDRA Life Sciences (NASDAQ: NDRA) hat sein 17. europäisches Patent (EP4247282) für ein neuartiges Verfahren zur Überwachung der Gewebetemperatur während minimalinvasiver thermischer chirurgischer Eingriffe mit ihrem TAEUS® System erhalten. Das Patent bezieht sich auf die Überwachung der Gewebeablation und ermöglicht die Integration mit bestehenden Ablationssystemen. Die Technologie ist auf thermische Ablationsverfahren mit Mikrowellen und Radiofrequenz anwendbar, die weltweit als weniger invasive Alternativen zu offenen Operationen zunehmen. Diese Ergänzung bringt ENDRAs глобale geistige Eigentumsportfolio auf 82 erteilte Patente in wichtigen Märkten einschließlich der Vereinigten Staaten, Europa und China.
- Expansion of intellectual property portfolio with 17th European patent
- Technology applicable to growing market of minimally invasive procedures
- Total of 82 patents issued worldwide across key markets
- None.
Insights
This patent issuance strengthens ENDRA's intellectual property position in thermal ablation monitoring, but has minimal immediate financial impact. The TAEUS® technology's application in minimally invasive surgical procedures represents a potential future revenue stream, though commercialization timeline remains unclear. The expansion to 82 total patents globally demonstrates R&D progress, but the company's micro-cap status (
Global Intellectual Property Portfolio Now Includes 82 Issued Patents
The ‘282 patent relates to a novel method and system for monitoring tissue ablation during minimally invasive thermal surgical interventions by utilizing ENDRA’s TAEUS® system. It is related to ENDRA’s
“This issued patent, our 17th in
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including non-invasive visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; ENDRA’s ability to maintain compliance with Nasdaq listing standards; ENDRA’s dependence on its senior management team; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106218099/en/
Company Contact:
Richard Jacroux
Chief Financial Officer
investors@endrainc.com
www.endrainc.com
Investor Relations:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com
Source: ENDRA Life Sciences Inc.
FAQ
What is ENDRA Life Sciences' (NDRA) latest European patent about?
How many patents does ENDRA Life Sciences (NDRA) now hold globally?